SESSION X: AGGRESSIVE B-CELL LYMPHOMA

Session Chairs:  Jason R. Westin, MD, MS, FACP and Jennifer Crombie, MD

Is It Time for Tailored Therapy in Frontline DLBCL? | Jason R. Westin, MD, MS, FACP | MD Anderson Cancer Center, Houston, Texas, USA

When Should Bispecific Antibodies Be Used in Aggressive B-Cell Lymphoma? | Jeremy S. Abramson, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Holding and Bridging Therapy Selection in Relapsed/Refractory Aggressive B-Cell Lymphoma | Gloria Iacoboni, MD, PhD | Vall d’Hebron Institute of Oncology, Barcelona, Spain

Treatment Approaches for Transformed Lymphoma | Jennifer Crombie, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Treatment of Rarer Subtypes of Aggressive B-Cell Lymphoma: TCRBCL, EBV-Positive DLBCL and Plasmablastic Lymphoma | Mark J. Roschewski, MD | NCI Center for Cancer Research, Bethesda, Maryland, USA

What Is the Potential of AI Remote Patient Monitoring for Lymphoma? | Jonas Paludo, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Oral Abstract TBA | Speaker | Affiliation, City, State, Country